Purpose. Ocular growth is regulated locally by signals produced in the retina. The highly heterogeneous nature of the retina may mask important changes in gene expression during global analysis. This study was conducted to investigate changes in gene expression specifically within the amacrine cell layer (ACL), the most likely generator of growth signals, during optical manipulation of ocular growth.

Method. Chicks were monocularly treated with either −7-D (n = 6) or +7-D (n = 6) lenses for 24 hours. Untreated age-matched chicks served as control subjects (n = 6). Total RNA from the ACL was isolated from 10-μm-thick sections, obtained using laser capture microdissection. Labeled cRNA was prepared from three samples per condition and hybridized to chicken genome microarrays. Changes in gene expression were validated by using semi-quantitative real-time RT-PCR.

Results. One hundred twenty-eight genes were differentially expressed in the ACL of the minus lens–treated eyes, whereas the plus lens–treated eyes displayed 58 changes 24 hours after treatment. Only 11 genes were differentially expressed under both experimental conditions, whereas the expression of only one gene (clone ChEST927g14) was modulated by the sign of defocus. Compared with previous studies in the field, the magnitude of changes observed in the present work were larger, with more than 50% of differentially expressed genes showing a twofold or greater modulation in expression. The results, obtained from independent validation by real-time RT-PCR technology, correlated highly with the original microarray data. The differential expression of four of eight genes was validated in plus lens–treated eyes, and eight of nine genes were independently validated in minus lens–treated eyes.

Conclusions. The targeted investigation of the ACL enabled the identification of several novel genes that may form part of the biochemical pathways underlying ocular growth. Different retinal pathways may underlie the response of the eyes to plus and minus lens compensation, as there was limited overlap in the regulated genes observed within the ACL under both conditions.

Myopia is an ocular disorder brought about by a mismatch between the axial length of the eye and its optical properties. This mismatch causes the focal plane of distant objects to fall in front of the retina when the eye is at rest, instead of on it, causing the images to appear blurred. In most cases, myopia is the result of excessive elongation of the eye, rather than alterations in the optical properties of either the cornea or lens. Myopia has emerged as a major epidemic in many parts of the world, most notably in urban East Asia, with a prevalence of up to 80% to 90% and at least 20% having high myopia (< −6 D), leading to an increased risk of chorioretinal degeneration.

Research into possible optical and pharmacologic treatments for prevention of myopia, and particularly high myopia, has been aided by the discovery that the rate of eye growth can be manipulated experimentally in animal models by altering their visual experience during deprivation of form vision or the fitting of spectacle lenses in front of the eye. The fitting of minus lenses over the eye pushes the image plane behind the retina, causing hyperopic defocus. This effect induces an increase in the rate of ocular growth, through rapid thinning of the choroid and the slower process of increased scleral growth, allowing the retina to be moved toward the correct focal plane. In contrast, the fitting of plus lenses in front of the eye causes the image plane to fall in front of the retina, producing myopic defocus. The eye compensates for the imposed defocus by pushing the retina forward toward the new focal plane through rapid swelling of the choroid and, more slowly, a reduction in the rate of scleral growth.

The pathways and molecules involved in the regulation of ocular growth are still unclear. Animal studies have demonstrated that eye growth is actively regulated, in response to visual stimuli, by local retinal mechanisms that send signals to, or past, the RPE/choroid to control the growth of the scleral tissue. Consequently, several studies have been undertaken to investigate global changes in retinal gene and protein expression during manipulation of ocular growth, in an attempt to elucidate the biochemical pathways underlying it. However, because of the highly heterogeneous nature of the retina, differential gene expression within subpopulations of retinal cells could mask important changes in gene and protein expression when investigated at the whole retinal level.

Retinal amacrine cells appear to be critically involved in the modulation of ocular growth. In support of this conclusion, animal studies have demonstrated that amacrine cells express and/or release numerous biochemical markers postulated to be involved in the modulation of ocular growth, including: Egr-1, Egr-2, glucagon, dopamine, Pax6, cellular retinoic acid binding protein (CRABP), retinoic acid receptor (RAR), cytochrome-c oxidase, vasoactive intestinal polypeptide (VIP), furthermore, key pharmacologic agents found to influence ocular growth specifically target transmitter systems expressed by the amacrine cells, whereas neural toxins that alter eye growth commonly target these retinal neurons. Therefore, we focused specifically on changes in RNA transcript levels within the amacrine cell layer (ACL) of the chick eye, a well-established model for eye growth, during visual manipulation of ocular growth.
most changes observed represent differential gene expression within retinal amacrine cells, this fundal layer is complex and also contains cell bodies of displaced bipolar and ganglion cells, as well as the processes of bipolar cells and Müller cells. Also, displaced amacrine cells, as well as those amacrine cells that sit deeper within the inner nuclear layer, may be missed. However, in general, the extracted sample of tissue is enriched in amacrine cell bodies.

**Methods**

**Animal Housing**

One-day-old white leghorn chicks were obtained from a local hatchery in Kirchberg, Germany. The chicks were maintained in temperature-controlled rooms under a 12:12 hour light–dark cycle, with incandescent illumination of ~500 lux during the light phase, and <1 lux in the dark phase (lights on at 7 AM and off at 7 PM). Chickens had access to unlimited amounts of food and water and were given 5 days to become accustomed to their surroundings before the commencement of experiments. All experiments conformed to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the University Commission for Animal Welfare.

**Experimental Treatment**

The methods used for lens-induced changes in ocular growth have been published in detail. Briefly, on the day before treatment, 7-day-old chicks were anesthetized with diethyl-ether and fitted with a ring (Velcro; Velcro GmbH, Freiberg am Neckar, Germany) attached around the left eye with super glue. On the following day, the chicks were split into three experimental groups: (1) minus lens–treated (n = 6), (2) plus lens–treated (n = 6), and (3) age-matched untreated control (n = 6). All animals were exposed to the treatment regimen for 24 hours beginning at 12 PM. For the lens-treated groups, either a -7-D lens, -7-D lens, or no lens wear (n = 5 per group). Retinal punches from the left eye were prepared carefully to ensure that the samples were not contaminated with retinal pigment epithelium and then immediately snap-frozen in liquid nitrogen and stored at −70°C. RNA was extracted (RNase Mini Kit, Qiagen, Hilden, Germany), according to the manufacturer’s instructions.

**Laser Capture Microdissection**

For LCM, frozen sections were allowed to thaw briefly (1 minute) before fixation in chilled (4°C) 70% ethanol for 2 minutes. The sections were briefly stained (1 minute) in 1% crystal violet for visualization of the retinal layers. The slides were then taken through a dehydration series (70%, 85%, 95%, and 100% ethanol, 1 minute per concentration), before being washed twice in xylene for 2 minutes per period, to remove any remaining alcohol. The sections were air dried in a fume hood (~3 minutes) to remove the remaining xylene, before being immediately placed on the microdissection stage for processing. A microbeam laser capture system (PALM; Carl Zeiss Meditec) was used to remove the ACL (Fig. 1) from eight sections per eye for later analysis by microarray.

**Microarray Analysis**

Roughly 0.3 ng of total RNA was extracted from LCM sections (RNase Mini Kit, Qiagen), according to the manufacturer’s instructions. Microarray analysis was performed by the Affymetrix Resource Facility (University of Tübingen, Germany) on three of the six samples collected for each experimental treatment (minus lens wear, plus lens

![Figure 1](Image)

**Figure 1.** (A) A retinal section after LCM of the ACL. (B) A retinal section after catapulting and collection of the ACL. RPE, retinal pigment epithelium; PRL, photoreceptor layer; OPL, outer plexiform layer; INL, inner nuclear layer; ACL, amacrine cell layer; IPL, inner plexiform layer; GCL, ganglion cell layer.
wear, and untreated control). The methods used for the preparation and analysis of samples by microarray technology (Affymetrix; Santa Clara, CA) have been described in detail.9 In brief, RNA quality and quantity were checked (model 2100 Bioanalyzer; Agilent Technologies, Böblingen, Germany) and a nanodrop system (ND1000; PeQlab, Erlangen, Germany). Total RNA was reverse transcribed to cDNA using oligo(dT) primers containing a T7 RNA polymerase promoter. After cDNA synthesis in the first cycle, an unlabeled ribonucleotide mix was used in the first cycle of in vitro transcription amplification. The unlabeled cRNA was then reverse transcribed in the first-strand cDNA synthesis step of the second cycle using random primers. Subsequently, a T7-Oligo (dT) promoter primer was used in the second-strand cDNA synthesis to generate double-stranded cDNA template containing a T7 promoter. The resulting double-stranded cDNA was amplified and labeled with a biotinylated nucleotide analogue/ribonucleotide mix in a second in vitro transcription reaction. The labeled cRNA samples were then cleaned up, fragmented, and hybridized onto gene microarray chips (Chicken Genome Array Chips; Affymetrix), according to the manufacturer’s protocol, with a coverage of 32,773 transcripts, corresponding to more than 28,000 chicken genes. Scanning and analysis of the chips was performed (Microarray Suite Software, ver. 5.0: Affymetrix) and the signal intensities analyzed (ArrayAssist 5.5.1; Stratagene, La Jolla, CA). GC RNA normalization data were corrected for multiple testing by using the Benjamini-Hochberg test with a false discovery rate of 5%. Microarray data were analyzed by using a GC-RMA normalization method, as it produces fewer false positives than Mas5 normalization, while accounting for sequence-specific probe affinities of the microarray probes to attain more accurate gene expression values than its predecessor (RMA normalization). The generated gene lists for RMA and Mas5 normalization can be found within the supplementary material, available at http://www.iovs.org/cgi/content/full/51/7/3726/DC1. All primary microarray data have been deposited in the Gene Expression Omnibus database (accession number GSE17758) (GEO; http://www.ncbi.nlm.nih.gov/geo; maintained in the public domain by The National Center for Biotechnology Information, Bethesda, MD).

Semiquantitative Real-Time RT-PCR

Fourteen genes of interest were chosen for further analysis and validation using real-time RT-PCR (Table 1). Two micrograms of total RNA was reverse transcribed to first-strand cDNA with a superscript cDNA Table 1. Sequences and Efficiency Values for Gene Specific Primers Used in Real-Time RT-PCR

<table>
<thead>
<tr>
<th>Gene No.</th>
<th>Gene Name</th>
<th>Gene Symbol</th>
<th>Forward Sequence</th>
<th>Reverse Sequence</th>
<th>Probe ID</th>
<th>Efficiency</th>
<th>Product Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Angiopoietin</td>
<td>ANGPT2</td>
<td>GCACCAGATGCCGTATTGCCT</td>
<td>CACTGAGAGGCTACTGTTTC</td>
<td>Gga.3259.1.S1_at</td>
<td>1.89</td>
<td>251</td>
</tr>
<tr>
<td>2</td>
<td>ChEST267a2</td>
<td>ChEST267a2</td>
<td>GCAAAGAGAAGCCAGTGGAA</td>
<td>CTAGGCCAGCAGCAGTGATT</td>
<td>Gga.10694.1.S1_at</td>
<td>1.88</td>
<td>110</td>
</tr>
<tr>
<td>3</td>
<td>ChEST49o10</td>
<td>ChEST49o10</td>
<td>GCCCTCCTGCTAAGACTGAA</td>
<td>GCCGATGAAGCAGAAAGGAA</td>
<td>Gga.13753.1.S1_at</td>
<td>2.08</td>
<td>170</td>
</tr>
<tr>
<td>4</td>
<td>Cytochrome</td>
<td>CYP26A1</td>
<td>GCCGATCTCTTTTACCAGCAA</td>
<td>GCGATTTGACCACAGGGTAC</td>
<td>Gga.331.1.S1_at</td>
<td>1.92</td>
<td>247</td>
</tr>
<tr>
<td>5</td>
<td>Zinc finger, DHHK-type containing 14</td>
<td>DHHC14</td>
<td>CATGCCACGCTACATGATGTC</td>
<td>CACTCTCTCTAGGAGAGGCA</td>
<td>GgaAffx.21352.1.S1_at</td>
<td>1.91</td>
<td>184</td>
</tr>
<tr>
<td>6</td>
<td>Di, zinc and double PHD fingers, family 5</td>
<td>DPF3</td>
<td>ACTGCTATAGCTAGTTGCCTG</td>
<td>TTGGGAGTAGAACAAGCTGGT</td>
<td>Gga.46.1.S1_a_at</td>
<td>1.93</td>
<td>206</td>
</tr>
<tr>
<td>7</td>
<td>Guanine nucleotide binding protein gamma 13</td>
<td>GNG13</td>
<td>TGCTCTCTCAAGAGATACCC</td>
<td>CACTTCCCCTTTTTCAGGACCA</td>
<td>Gga.10842.1.S1_at</td>
<td>1.83</td>
<td>115</td>
</tr>
<tr>
<td>8</td>
<td>Gial cell line derived neurotrophic factor, family receptor alpha 1</td>
<td>GFRA1</td>
<td>AAGTGATTTCTGCGTGCCTG</td>
<td>GAGCTTTGCAAAAGGCTGGT</td>
<td>Gga.588.1.S1_at</td>
<td>1.89</td>
<td>193</td>
</tr>
<tr>
<td>9</td>
<td>General transcription factor IIH, polypeptide 5</td>
<td>GTF2H5</td>
<td>ATGCGACATCCCATGACTAC</td>
<td>CACTCCCAAAACTCGAACA</td>
<td>GgaAffx.12217.1.S1_at</td>
<td>1.89</td>
<td>188</td>
</tr>
<tr>
<td>10</td>
<td>Similar to lymphocyte binding protein 64</td>
<td>CD180</td>
<td>CGCTGTCAGCCGACAGATGTC</td>
<td>CGCCAGGCAAAACACATGAC</td>
<td>Gga.7810.1.S1_at</td>
<td>1.94</td>
<td>158</td>
</tr>
<tr>
<td>11</td>
<td>LOC425969</td>
<td>LOC425969</td>
<td>GCACTGATCCACCAATGGCT</td>
<td>CCGACATCTTTGTGCTGCTA</td>
<td>Gga.6572.1.A1_at</td>
<td>1.92</td>
<td>144</td>
</tr>
<tr>
<td>12</td>
<td>Homeobox; mshlike 2</td>
<td>MSHX2</td>
<td>GCCGCTGAACTGCTTCTGCTA</td>
<td>CAGTGTGCTGACCTCGTCTT</td>
<td>Gga.4977.1.S1_at</td>
<td>1.86</td>
<td>135</td>
</tr>
<tr>
<td>13</td>
<td>Protein-kinase, interferon-inducible RNA inhibitor</td>
<td>PRKRR</td>
<td>GCTGCTTCTGCTGCTGGAAATG</td>
<td>CGACTATCCTGGCTGCTGTT</td>
<td>GgaAffx.20873.1.S1_at</td>
<td>1.86</td>
<td>150</td>
</tr>
<tr>
<td>14</td>
<td>Rab22a</td>
<td>Rab22a</td>
<td>CTGTGTCGAGAGGAGAGGAGAG</td>
<td>CTTGAGACGGCGCGGATGAGT</td>
<td>Gga.7554.1.S1_s_at</td>
<td>1.90</td>
<td>215</td>
</tr>
</tbody>
</table>

Beta-Actin | β-Acin | HPR | TGGCAGACATGAGAGGAGGAG | GCGATTTGACCGCGGACGAC | Gta.13753.1.S1_at | 1.95       | 148          |

Hypoxanthine phosphoribosyl transferase
Microarray Validation

From the list of differentially expressed genes, generated by using a GC-RMA normalization method, 14 candidate genes were chosen for further analysis by real-time RT-PCR, based on previously defined roles within the body; pathway analysis, abundance in the ACL; and an appreciably large change ratio and/or probability. In general, the results obtained from microarray and real-time RT-PCR technologies correlated highly ($r = 0.85x + 1.32, r^2 = 0.49, P < 0.001$), with the exclusion of ChEST490i10, which was $>3$ SD outside the mean. All 14 candidate genes, whether differentially expressed in plus or minus tissue, were analyzed in both treatment groups via real-time RT-PCR.

Validation of Gene Expression Data in Microdissected ACL Samples. It was possible to validate eight of nine genes indicated to be differentially expressed in the minus lens-treated eyes (Fig. 2): validated genes included angiopoietin 2 (ANGPT2), ChEST267a2, ChEST490i10, D4, zinc and double PHD fingers, family 3 (DPF3), guanine nucleotide binding protein, gamma 13 (GNG13), glial cell–derived neurotrophic factor family receptor alpha 1 (GFR1A1), CD180 antigen (CD180), and LOCA5690, while the nonvalidated genes included zinc finger DHHC domain-containing protein 14 (DHHC14). In plus lens-treated samples (Fig. 3), it was possible to validate four of eight genes indicated to be differentially expressed, including the validated genes GFR1A1, general transcription factor IIIH, polypeptide 5 (GTF2H5), LOC425690, and Rabb22a, while those genes which were not validated by RT-PCR included cytochrome P450, family 26, subfamily a, polypeptide 1 (CYP26A1), DHHC14, Msh homeobox 2 (MNX2), protein kinase, interferon-inducible double-stranded RNA-dependent (PKRBD) from the double amplified microdissected ACL samples. We also confirmed that there was no change in the expression of the remaining five candidate genes investigated in the minus lens-treated eyes (Table 2) and in four of five of the candidate genes in the plus lens-treated samples (Table 3), with the exception of the cDNA clone ChEST490i10, which showed a differential expression via PCR ($P = 0.01$) that was not observed by gene microarray ($P = 0.15$). In general, 75% (13/18 in the minus lens-treated group, 8 of 14 in the plus lens-treated group) of the investigated changes in gene expression were independently validated by semiquantitative RT-PCR, which included those genes indicated by microarray analysis not to display any change in expression level in response to plus or minus lens wear.

Comparison of Gene Expression Levels between the Whole Retina and the Amacrine Cell Layer. The expression levels of the candidate genes were measured within the whole retina to determine whether the observed changes were or were not confined to the ACL. We observed only two significant changes in transcript levels within the whole retina of the minus lens–treated eyes (DPF3 and GNG13; Table 2); no significant changes were observed within the whole retina of the plus lens–treated eyes (Table 3).

Pathway Analysis

Human orthologues of GC-RMA normalized data were further analyzed (Pathways Analysis Software; Ingenuity Systems). The functional interactions between proteins and molecules that are shown in the proposed networks are supported by published information that is associated by the program with known biological pathways. The software suggested five distinct gene interaction pathways within the ACL of the minus lens–treated eyes and two in the plus lens–treated eyes (Fig. 4, Supplementary Figs. S1–S6). The major pathway predicted for the plus lens–treated eyes, in which 11 of 35 genes were found to be differentially expressed, was further analyzed (Fig. 4, differentially expressed genes are displayed in black). Using real-time RT-PCR, we investigated 5 of these 11 differentially expressed genes and validated the differential expression of Rab22a, Egfr-1, and GTF2H5.

DISCUSSION

Gene microarray analysis of LCM tissue detected 186 differentially expressed genes within the ACL of the chick retina in synthesis...
FIGURE 2. Candidate gene transcript levels in the ACL of minus lens-treated eyes, as detected by microarray analysis and real-time RT-PCR. Changes in gene expression are expressed as ratios ± SD. *P < 0.05, **P < 0.01.

FIGURE 3. Candidate gene transcript levels in the ACL of plus lens-treated eyes, as detected by microarray analysis and real-time RT-PCR. Changes in gene expression are presented as ratios ± SD. *P < 0.05, **P < 0.01.
response to 24 hours of visual manipulation with spectacle lenses, with a larger number of changes observed in response to enhanced ocular growth (128 genes, minus lens wear), as opposed to growth suppression (56 genes, plus lens wear). In comparison to previous studies within the field, the magnitude of changes observed in this study was, in general, larger, with greater than 50% of differentially expressed genes showing a twofold or greater modulation in expression. This larger magnitude most likely represents a reduction in both noise and masking of transcript levels due to the more homogenous tissue sample analyzed presently. Only 11 genes were differentially expressed under both experimental conditions; the expression of only one (clone ChEST927g14) was dependent on the sign of focus. These results suggest that different retinal pathways are involved in plus and minus lens compensation, at least after 1 day of treatment. Most changes observed by microarray analysis should represent differential gene expression within retinal amacrine cells. Nevertheless, this fundal layer also contains the cell bodies of displaced bipolar and ganglion cells, as well as the processes of bipolar cells and Müller cells.

### Independent Validation of Microarray Analysis

Validation of microarray data was undertaken using independent mRNA quantification techniques (real-time RT-PCR), with validation taken as a change >1.5-fold and \( P < 0.05 \). In general, the results from microarray and real-time RT-PCR technologies correlated highly, with 75% of the investigated genes independently validated, including those indicated by microarray analysis to have shown no change in expression level. The inability, however, to correlate changes in 25% of our investigated genes emphasizes the need for caution in interpreting gene expression data and may result from several issues, including the existence of nonspecific or alternative transcripts that cross-hybridize with the microarray probes, the existence of multiple isoforms of the gene differentially detected by microarray analysis and RT-PCR, and differences in normalization methodology between PCR and microarray analysis.

### Pathway Analysis

Analysis of microarray data (Pathway Analysis; Ingenuity Systems) suggested five distinct pathways within the ACL of the

---

### Table 2. Validation of Candidate Genes from Minus Lens–Treated Eyes, According to Real-Time RT-PCR

<table>
<thead>
<tr>
<th>Gene No.</th>
<th>Gene Name</th>
<th>Probe ID</th>
<th>FC-Chip</th>
<th>P</th>
<th>FC-PCR</th>
<th>P</th>
<th>FC-WR</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ANGPT2</td>
<td>Gga.3259.1.S1_at</td>
<td>2.7</td>
<td>0.02</td>
<td>4.5</td>
<td>0.01</td>
<td>−1.2</td>
<td>0.71</td>
</tr>
<tr>
<td>2</td>
<td>ChEST2676a2</td>
<td>Gga.10694.1.S1_at</td>
<td>−5.8</td>
<td>0.002</td>
<td>−4.7</td>
<td>0.05</td>
<td>1.0</td>
<td>0.83</td>
</tr>
<tr>
<td>3</td>
<td>ChEST949a10</td>
<td>Gga.13755.1.S1_at</td>
<td>−27.4</td>
<td>0.01</td>
<td>−2.7</td>
<td>0.03</td>
<td>1.0</td>
<td>0.90</td>
</tr>
<tr>
<td>4</td>
<td>CYP26A1</td>
<td>Gga.351.1.S1_at</td>
<td>−3.1</td>
<td>0.06</td>
<td>1.6</td>
<td>0.48</td>
<td>−1.2</td>
<td>0.62</td>
</tr>
<tr>
<td>5</td>
<td>DHHC14</td>
<td>GgaAffx.21352.1.S1_at</td>
<td>−2.2</td>
<td>0.03</td>
<td>1.0</td>
<td>0.98</td>
<td>1.6</td>
<td>0.58</td>
</tr>
<tr>
<td>6</td>
<td>DF53</td>
<td>Gga.46.1.S1_at</td>
<td>4.6</td>
<td>0.009</td>
<td>7.5</td>
<td>0.02</td>
<td>2.8</td>
<td>0.03</td>
</tr>
<tr>
<td>7</td>
<td>GNG13</td>
<td>Gga.10842.1.S1_at</td>
<td>2.6</td>
<td>0.0002</td>
<td>3.7</td>
<td>0.03</td>
<td>1.3</td>
<td>0.02</td>
</tr>
<tr>
<td>8</td>
<td>GFRA1</td>
<td>Gga.588.1.S1_at</td>
<td>3.7</td>
<td>0.0009</td>
<td>5.6</td>
<td>0.03</td>
<td>1.8</td>
<td>0.55</td>
</tr>
<tr>
<td>9</td>
<td>GTF2H5</td>
<td>GgaAffx.12217.1.S1_at</td>
<td>1.1</td>
<td>0.96</td>
<td>1.8</td>
<td>0.08</td>
<td>1.6</td>
<td>0.87</td>
</tr>
<tr>
<td>10</td>
<td>CD180</td>
<td>Gga.7810.1.S1_at</td>
<td>−3.9</td>
<td>0.007</td>
<td>−2.9</td>
<td>0.04</td>
<td>−1.2</td>
<td>0.17</td>
</tr>
<tr>
<td>11</td>
<td>LOC425969</td>
<td>Gga.6572.1.A1_at</td>
<td>−3.9</td>
<td>0.0001</td>
<td>−4.4</td>
<td>0.02</td>
<td>−2.8</td>
<td>0.36</td>
</tr>
<tr>
<td>12</td>
<td>MSX2</td>
<td>Gga.4977.1.S1_at</td>
<td>−1.5</td>
<td>0.7</td>
<td>1.0</td>
<td>0.98</td>
<td>−2.6</td>
<td>0.13</td>
</tr>
<tr>
<td>13</td>
<td>PRKRR</td>
<td>GgaAffx.20873.1.S1_at</td>
<td>1.0</td>
<td>0.96</td>
<td>1.2</td>
<td>0.88</td>
<td>1.0</td>
<td>0.97</td>
</tr>
<tr>
<td>14</td>
<td>Rab22a</td>
<td>Gga.7554.1.S1_s_at</td>
<td>2.0</td>
<td>0.35</td>
<td>10.0</td>
<td>0.16</td>
<td>−1.2</td>
<td>0.53</td>
</tr>
</tbody>
</table>

Changes in gene expression are represented as the ratio of change, with a change of 1 equaling no change in gene expression and a change of 2 equaling a doubling in product. Minus values represent a reduction in gene expression. Probability values in bold represent statistically significant changes in RNA transcript levels \( (P \leq 0.05) \). FC, change ratio \( (x\text{-fold}); \) Chip, expression of candidate genes on the Affymetrix chips \( (n = 3, \) per experimental condition); PCR, PCR results from double-amplified LCM tissue processed for microarray analysis \( (n = 6, \) per experimental condition); WR, PCR results from whole retinal samples \( (n = 5, \) per experimental condition).

### Table 3. Validation of Candidate Genes, from Plus Lens–Treated Eyes, According to Real-Time RT-PCR

<table>
<thead>
<tr>
<th>Gene No.</th>
<th>Gene Name</th>
<th>Probe ID</th>
<th>FC-Chip</th>
<th>P</th>
<th>FC-PCR</th>
<th>P</th>
<th>FC-WR</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>ANGPT2</td>
<td>Gga.3259.1.S1_at</td>
<td>1.4</td>
<td>0.38</td>
<td>1.3</td>
<td>0.76</td>
<td>1.2</td>
<td>0.13</td>
</tr>
<tr>
<td>2</td>
<td>ChEST2676a2</td>
<td>Gga.10694.1.S1_at</td>
<td>−1.6</td>
<td>0.27</td>
<td>1.4</td>
<td>0.21</td>
<td>1.6</td>
<td>0.07</td>
</tr>
<tr>
<td>3</td>
<td>ChEST949a10</td>
<td>Gga.13755.1.S1_at</td>
<td>−5.1</td>
<td>0.15</td>
<td>−5.1</td>
<td>0.01</td>
<td>1.3</td>
<td>0.32</td>
</tr>
<tr>
<td>4</td>
<td>CYP26A1</td>
<td>Gga.351.1.S1_at</td>
<td>−3.6</td>
<td>0.03</td>
<td>1.1</td>
<td>0.94</td>
<td>1.0</td>
<td>0.98</td>
</tr>
<tr>
<td>5</td>
<td>DHHC14</td>
<td>GgaAffx.21352.1.S1_at</td>
<td>−2.3</td>
<td>0.03</td>
<td>1.0</td>
<td>0.98</td>
<td>1.0</td>
<td>0.94</td>
</tr>
<tr>
<td>6</td>
<td>DF53</td>
<td>Gga.46.1.S1_at</td>
<td>2.7</td>
<td>0.051</td>
<td>−4.3</td>
<td>0.70</td>
<td>1.7</td>
<td>0.44</td>
</tr>
<tr>
<td>7</td>
<td>GNG13</td>
<td>Gga.10842.1.S1_at</td>
<td>1.4</td>
<td>0.051</td>
<td>1.5</td>
<td>0.80</td>
<td>1.3</td>
<td>0.22</td>
</tr>
<tr>
<td>8</td>
<td>GFRA1</td>
<td>Gga.588.1.S1_at</td>
<td>3.8</td>
<td>0.0007</td>
<td>2.4</td>
<td>0.04</td>
<td>1.1</td>
<td>0.92</td>
</tr>
<tr>
<td>9</td>
<td>GTF2H5</td>
<td>GgaAffx.12217.1.S1_at</td>
<td>2.2</td>
<td>0.03</td>
<td>3.7</td>
<td>0.03</td>
<td>1.4</td>
<td>0.58</td>
</tr>
<tr>
<td>10</td>
<td>CD180</td>
<td>Gga.7810.1.S1_at</td>
<td>1.0</td>
<td>0.99</td>
<td>1.7</td>
<td>0.14</td>
<td>1.0</td>
<td>0.79</td>
</tr>
<tr>
<td>11</td>
<td>LOC425969</td>
<td>Gga.6572.1.A1_at</td>
<td>−3.1</td>
<td>0.002</td>
<td>−2.7</td>
<td>0.01</td>
<td>−1.8</td>
<td>0.56</td>
</tr>
<tr>
<td>12</td>
<td>MSX2</td>
<td>Gga.4977.1.S1_at</td>
<td>−2.0</td>
<td>0.014</td>
<td>−1.4</td>
<td>0.72</td>
<td>−1.5</td>
<td>0.36</td>
</tr>
<tr>
<td>13</td>
<td>PRKRR</td>
<td>GgaAffx.20873.1.S1_at</td>
<td>2.3</td>
<td>0.02</td>
<td>1.7</td>
<td>0.32</td>
<td>−1.2</td>
<td>0.43</td>
</tr>
<tr>
<td>14</td>
<td>Rab22a</td>
<td>Gga.7554.1.S1_s_at</td>
<td>2.2</td>
<td>0.004</td>
<td>6.5</td>
<td>0.03</td>
<td>−1.7</td>
<td>0.11</td>
</tr>
</tbody>
</table>

Changes in gene expression and explanation of column headings are as defined in Table 2. Probability values in bold represent statistically significant changes in RNA transcript levels \( (P \leq 0.05) \).
minus lens-treated samples and three in the plus lens-treated samples. These pathways are based on known human gene interactions, primarily within nonocular tissues. Detailed investigation of the major pathway predicted for the plus lens-treated samples, in which 11 of 35 genes were found to be differentially expressed (5 of which were investigated further), validated three of five changes (Egr-1, GTF2H5, and Rab22a). This predicted pathway, which warrants further investigation, was broadly defined as relating to cell signaling, development, and assembly. Key peptides within this predicted pathway included Egr-1, already postulated to play a key role in the regulation of ocular growth; β-estradiol; and hepatocyte nuclear factor 4, alpha (HNF4α). β-Estradiol is a steroid hormone synthesized mainly within the ovaries and to a lesser extent within peripheral tissues, including the retina. β-Estradiol appears to have neurotrophic and neuroprotective properties, increasing viability, survival, and differentiation of primary neurons in culture, and protecting retinal neurons against insults such as light damage and hydrogen peroxide treatment.33,34 HNF4α encodes for a nuclear transcription factor that regulates the expression of numerous genes including members of the cytochrome P450 (CYP) family and HNF1.35

Gene Expression at the Whole Retina Level

Only two statistically significant changes, those of DPF3 and GNG13, were observed within the whole retina of the eyes treated for 24 hours with minus lenses. No differential expression in transcript levels was observed in the whole retina of the plus lens-treated eyes. These findings support the hypothesis that changes in gene expression within the whole retina mask more specific changes occurring within the ACL. It should be noted though that RNA levels of the candidate genes, within the whole retina, were quite low and may therefore have reduced our ability to detect changes in their expression levels. In general, however, the lack of correlation between the changes seen within the ACL and whole retina emphasizes the possible loss of information, because of the heterogeneous nature of the retina, when investigating global changes in gene expression.

Comparison with Other Profiling Studies

A comparison of our current GC-RMA normalized microarray data, for both the plus- and minus lens-treated animals, against similar genetic studies in the field, indicated limited overlap in gene lists. The reduced overlap with previous microarray findings was, to some extent, expected, as these studies focused on changes in gene expression across the whole retina, or in some cases retina-RPE, or the retina-RPE-choroid. In contrast, we report in this study on the differential regulation of gene expression within a specific fundus layer of the eye, thereby significantly reducing the subtypes of ocular cells sampled compared with previous microarray studies.

A small number of genes, reported previously to be differentially expressed in response to visual manipulation, appeared on our current GC-RMA list. Comparisons with the study of McGlinn et al.,7 who investigated changes in gene expression within a retinal-RPE tissue mix after 6 hours and 3 days of form deprivation (growth stimulant), indicated five common hits (LOC420181, PRKRI, SOUL, LOC419390, and LOC424393). Comparisons with the study by Schippert et al.,8 who investigated changes in gene expression within the retina of chicks treated for 1 day with plus lenses, indicated three common hits (Table 4; LOC424393, ChEST914α3, and Egr-1). They found the expression of Egr-1 to be lower in the whole retina (~2.6-fold), with a similar finding observed in the ACL (~2.1-fold) in the present study. As they discussed, the unexpected downregulation in Egr-1 expression suggests that the mRNA levels of this transcriptional regulator are upregulated in the short term (1–4 hours) by exposure to myopic defocus,56 but appear to be downregulated in response to longer periods (24 hours) of positive lens wear. Further studies are necessary to determine the time kinetics of changes in Egr-1 mRNA content in response to plus lens treatment.

No overlap was observed between our current findings and the other three major profiling studies.8,10,11 This general lack of overlap may be due to several key differences among the studies, including the type of ocular tissue analyzed, the length and choice of treatment regimens, the type and age of gene
chip technology used, the species investigated, and the normalization methods used. Furthermore, the current literature suggests that reliable and reproducible detection of changes in gene expression by microarray analysis can be achieved for transcripts that show high abundance and relatively large changes in expression. However, the reliable measurement of genes of low abundance, which display small changes, is not as easily achievable. As many of the gene expression changes according to microarray analysis in the field concern small changes in gene expression that show low abundance within the retina, this may further affect reproducibility between studies. Also, it has been noted that the reproducibility of microarray results is reduced if different array platforms are used, as opposed to comparisons between studies using similar platforms, in part because of identification of different splice variants of specific transcripts and differences in the amount and location of unwanted cross-hybridizations.

The Expression of Known Markers of Ocular Growth

Several genes that have been postulated to play a role in the regulation of ocular growth also showed small but significant changes in expression, as assessed by microarray analysis. RNA levels of pre-pro glucagon, a known inhibitor of experimental eye growth, showed a significant downregulation in response to minus lens wear, compared with those values seen within the ACL of the plus lens–treated eyes (P = 0.04). Cytochrome-c oxidase, subunit 1 mRNA levels have been shown by Feldkampfer et al. to be significantly upregulated in the retina in response to 1 day of plus lens wear. Analysis of our current data indicates that the expression of cytochrome-c oxidase, subunit 6, isoform 1 and cytochrome-c oxidase assembly protein was significantly upregulated in response to 24 hours of minus lens wear (P = 0.02, P = 0.04, respectively). Unfortunately, no probe was present on the current microarray chips for cytochrome-c oxidase, subunit 1. We also observed a small but significant reduction in RNA levels of vasoactive intestinal peptide (VIP) receptor 1 within the ACL in response to plus lens wear in comparison to the minus lens–treated samples (P = 0.03). Previous studies have reported a significant upregulation in the expression of VIP RNA1 and peptide levels in primates after lid suturing, whereas microarray analysis of the retina/RPE after 3 days of deprivation myopia have indicated a significant downregulation in RNA levels of VIP.

Several other molecules that have been proposed to play a role in the regulation of ocular growth were not observed to change in the present study, including members of the crystallin family (αA and αB, βαA, βα1, βB1, and βB2), bone morphogenetic protein 2, nitric oxide synthase, pax6, sox1/3, and sonic hedgehog. The overall lack of change in these molecules is most likely explained by differences in the time points measured, differences in the molecular level examined (e.g., peptide versus RNA), and differences in the treatment regimen used to elicit changes in their expression, as many of these changes have been reported in deprivation-myopia experiments, but not in lens paradigms. Most important, these molecules are probably not localized within the ACL. At least, no significant levels of crystallin, sox1, sonic hedgehog, and neuronal nitric oxide synthetase mRNA were detected in the present microarray analysis of the ACL.

The Detection of Novel Genes

The confirmed differential expression of several novel candidate genes could reflect a role for their peptide products in eye growth regulation in response to visual manipulation; however, they may also represent indirect responses to changes in global eye size and visual distortion induced by lens wear. Below, a brief description of the known biological role of each candidate gene for which differential expression was independently confirmed is given.

**Angiopoietin 2.** **ANGPT2** is a growth factor involved in physiological vasculogenesis and angiogenesis through binding to the Tie receptor family. It is also associated with pathologic neovascularization and diabetic macular edema and is known to be upregulated by hypoxia, retinal ischemia, and high glucose levels. Its expression is also induced by various cytokines, including fibroblast growth factor (FGF)-2, and vascular endothelial growth factor (VEGF), both of which have been postulated to play a role in the regulation of ocular growth (Nguyen KT, et al. IOVS 2009;50:ARVO E-Abstract 3840).

**D4, Zinc, and Double PHD Fingers, Family 3.** Because of the presence of a double-paired finger motif, it is assumed that **DPF3** (Cer-d4) is involved in neurospecific transcriptional regulation via changes in the condensed/decondensed state of chromatin in the nucleus. **DPF3** expression is observed in many parts of the peripheral and central nervous system, but is concentrated highly within both the retina and cerebellum.

**Guanine Nucleotide Binding Protein (G Protein), Gamma 13.** **GNG13** has been hypothesized to be involved in ON-bipolar cell signaling, with recent evidence from animal

### Table 4. Comparison of Current GC-RMA Normalized Microarray Data with Previous Microarray Studies in the Field

<table>
<thead>
<tr>
<th>Probe ID</th>
<th>Name</th>
<th>Treatment</th>
<th>Change Ratio</th>
<th>P</th>
<th>Change Ratio</th>
<th>P</th>
<th>Change Ratio</th>
<th>P</th>
<th>Change Ratio</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gga.24735.1.S1_at</td>
<td>LOC420181</td>
<td>Minus lens</td>
<td>2.0</td>
<td>0.005</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gga.20873.1.S1_at</td>
<td>PRKIR</td>
<td>Minus lens</td>
<td>2.2</td>
<td>0.010</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gga.1806.1.S1_at</td>
<td>SOUL</td>
<td>Minus lens</td>
<td>−1.6</td>
<td>0.027</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gga.9574.1.S1_at</td>
<td>LOC419390</td>
<td>Minus lens</td>
<td>2.0</td>
<td>0.005</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gga.9844.3.S1_at</td>
<td>LOC424593</td>
<td>Minus lens</td>
<td>−1.8</td>
<td>0.020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gga.8944.3.S1_at</td>
<td>LOC424593</td>
<td>Minus lens</td>
<td>−1.8</td>
<td>0.045</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Current Data**

- Probe ID: Gga.8944.3.S1_at
- Name: LOC424593
- Treatment: Minus lens
- Change Ratio: −1.8
- P: 0.002

**Current Data**

- Probe ID: Gga.8944.3.S1_at
- Name: LOC424593
- Treatment: Minus lens
- Change Ratio: −2.1
- P: 0.045

**McGlinn et al.**

<table>
<thead>
<tr>
<th>Probe ID</th>
<th>Name</th>
<th>Treatment</th>
<th>Change Ratio</th>
<th>P</th>
<th>Change Ratio</th>
<th>P</th>
<th>Change Ratio</th>
<th>P</th>
<th>Change Ratio</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gga.24735.1.S1_at</td>
<td>LOC420181</td>
<td>Plus lens</td>
<td>2.3</td>
<td>0.024</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gga.20873.1.S1_at</td>
<td>PRKIR</td>
<td>Plus lens</td>
<td>1.9</td>
<td>0.020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gga.1806.1.S1_at</td>
<td>SOUL</td>
<td>Plus lens</td>
<td>1.8</td>
<td>0.002</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gga.9574.1.S1_at</td>
<td>LOC419390</td>
<td>Plus lens</td>
<td>1.8</td>
<td>0.002</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gga.9844.3.S1_at</td>
<td>LOC424593</td>
<td>Plus lens</td>
<td>1.8</td>
<td>0.020</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Current Data**

- Probe ID: Gga.8944.3.S1_at
- Name: LOC424593
- Treatment: Plus lens
- Change Ratio: 1.6
- P: 0.027

**Current Data**

- Probe ID: Gga.8944.3.S1_at
- Name: LOC424593
- Treatment: Plus lens
- Change Ratio: 2.1
- P: 0.045

**Schippert et al.**

<table>
<thead>
<tr>
<th>Probe ID</th>
<th>Name</th>
<th>Treatment</th>
<th>Change Ratio</th>
<th>P</th>
<th>Change Ratio</th>
<th>P</th>
<th>Change Ratio</th>
<th>P</th>
<th>Change Ratio</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gga.24735.1.S1_at</td>
<td>LOC420181</td>
<td>FDM, 3 days</td>
<td>1.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gga.20873.1.S1_at</td>
<td>PRKIR</td>
<td>FDM, 3 days</td>
<td>1.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gga.1806.1.S1_at</td>
<td>SOUL</td>
<td>FDM, 3 days</td>
<td>1.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gga.9574.1.S1_at</td>
<td>LOC419390</td>
<td>FDM, 3 days</td>
<td>1.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gga.9844.3.S1_at</td>
<td>LOC424593</td>
<td>FDM, 3 days</td>
<td>1.2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Current Data**

- Probe ID: Gga.8944.3.S1_at
- Name: LOC424593
- Treatment: FDM, 3 days
- Change Ratio: 1.6
- P: 0.027

**Current Data**

- Probe ID: Gga.8944.3.S1_at
- Name: LOC424593
- Treatment: FDM, 3 days
- Change Ratio: 2.1
- P: 0.045

**Current Data**

- Probe ID: Gga.8944.3.S1_at
- Name: LOC424593
- Treatment: FDM, 3 days
- Change Ratio: 2.6
- P: <0.0001
studies suggesting that bipolar cells may be critically involved in the regulation of ocular growth.47–50

Glial Cell Line–Derived Neurotrophic Factor (GDNF) Family Receptor Alpha 1. GFRα1 is a glycosylphosphatidylinositol-linked cell surface receptor that binds, with high affinity, the potent neurotrophic factor GDNF, inducing activation of the RET protein-tyrosine kinase system. GDNF is critically involved in the development and maintenance of central and peripheral neurons, as well as the development of other organs, such as the kidney.51,52

General Transcription Factor III, Polypeptide 5. GTF2H5 is essential for RNA polymerase II transcription and nucleotide excision repair, as part of a multicellular complex with transcription repair factor IIH (TFIIH).53,54 Cells lacking GTF2H5 show reduced DNA repair activity, whereas yeast lacking this protein have been found to grow slowly and to be sensitive to UV radiation.54

CD180. Similar to lymphocyte-binding protein 64 this cell surface molecule belongs to the family of pathogen receptors (Toll-like receptors) that trigger innate immune responses, but are also involved in several other physiological functions including the regulation of retinal progenitor cell proliferation, RPE transmembrane signaling involved in photoreceptor disc shedding, establishing dorsal–ventral axis polarity, and synaptogenesis (for review, see Ref. 55).

Rab22a. This protein is a member of the Rab family of small GTPases, and is expressed ubiquitously in mammalian tissues. Rab proteins are involved in diverse functions associated with the control of intracellular membrane trafficking (for review, see Ref. 56).

LOC425969, ChEST267a2, and ChEST49o10. No information is currently available with regard to the structure or function of the ESTs ChEST267a2 and ChEST49o10 or the predicted protein LOC425969.

CONCLUSIONS
We successfully removed the ACL by LCM and analyzed changes in gene expression by using microarray analysis, after plus (suppressed ocular growth) and minus (ocular growth stimulation) lens treatment. GC-RNA normalization showed 186 changes in gene expression within the ACL in response to lens treatment. Most of these changes seem to be confined to the cells of the ACL since they were not observed within the whole retina. Moreover, we hypothesize that different retinal pathways may be involved in plus and minus lens compensation since there was limited overlap in the genes regulated by both conditions. From the list of differentially expressed genes, we have identified and validated several novel genes that may form part of the growth regulatory system of the eye.

Acknowledgments
The authors thank Eva Burkhardt and Monika Schuetz (Institute for Medical Microbiology and Hygiene, University of Tübingen) for technical assistance with PCR sequencing.

References


